Healthcare Merchant Banking

Exceeding client expectations around the globe

Bourne Partners offers a global reach and extensive experience with deals in more than 30 countries. Our management team is composed of former healthcare executives and seasoned investment bankers who have experienced both the operating and transactional sides of the industry. Together, we have raised over $2 billion in equity and debt capital and executed over $5 billion in healthcare and pharmaceutical M&A transactions. Currently, we maintain a close relationship and an active calling effort with more than 300 healthcare companies around the world.

Our track record includes not only advising middle market companies in over $5 billion in healthcare M&A assignments, but also growing companies into multimillion-dollar pharmaceutical enterprises. We have assisted owners of private companies in mergers, acquisitions, partnering/development, and the sale or refinancing of businesses. We know the industry, because we have been in the shoes of many of our clients as they consider various strategic alternatives. This knowledge makes our team uniquely positioned to provide advice based on true experience.

What Our Clients Say About Us

  • "I have worked with Banks in two separate organizations and hope to work together again in the future. Banks and his team are a high performance organization that consistently and creatively delivers value for their clients. We worked together as a corporate development team at a high-growth technology services firm and in investment banking at Wachovia Securities. His contributions were impressive, his work products excellent, and his negotiating and analytical skills formidable. I invite anyone with questions regarding Banks or his firm to contact me directly at any time for more specifics. He is a talented, rare individual."

    Charles Cox, Director Portfolio Management, Capitala Group

  • "Bourne Partners is very professional and responsive. They are true experts in the field."

    Woody Bryan, Vice President, Business Development, Supernus Pharmaceuticals

  • "Banks is a great resource - easy to work with, high integrity and very knowledgeable. I look forward to more opportunities to work together."

    David Sturdee, Managing Director, Clairvest

  • "We have worked successfully with Bourne Partners on several key projects recently and greatly value their industry insight, advice and perseverance."

    Jeff Rowan, Chief Executive Officer, Fleet Laboratories

  • "Banks and his team consistently offer the invaluable combination of strategic insight, execution capabilities and bold and honest yet personable communication skills. A trusted and important business partner!"

    Bob Lemon, Chief Financial Officer, Fleet Laboratories

  • "I would highly recommend Bourne Partners as a financial advisor to anyone in the healthcare industry."

    Jack Davis, Chief Executive Officer, Covis Pharma Holdings S.a.r.l.

  • "Bourne Partners was more than our investment bank, they were a value-added partner and extension of our management team.  Their team members brought both a unique financial and operational perspective, were extremely professional and have unparalleled knowledge of the healthcare industry.  Bourne’s investment and advisory experience, in combination with the resources they were able to bring to the table, were crucial in successfully closing our transaction with the best financial partner for Covis."

    Bill Collins, Founder, Covis Pharmaceuticals, Inc.

  • "I am very pleased to renew our association with the management team at Bourne Partners. We look forward to more opportunities to work with them to expand our investment opportunities and generate additional international business within our portfolio."

    John Gregory, Founder and Former CEO, King Pharmaceuticals

  • "We have worked with the team at Bourne Partners over a number of years on several transactions both in Europe and the United States. Their experienced bankers provide a high level of industry knowledge and deal making expertise within the middle market healthcare arena. The firm has been an invaluable financial advisor to Desitin, and we continue to utilize their group in evaluating various strategic opportunities."

    Martin Zentgraf, General Manager, Desitin Arzneimittel GmbH

  • "We are excited to partner with Bourne Capital Partners to jointly build CollMED Laboratories, a new advanced wound care business located in the United States. This is the second time we have worked with the Bourne team and look forward to future collaborations."

    Michael Myers, Chief Executive Officer, Innocoll Pharmaceuticals

  • "I have worked with the team at Bourne Partners on various initiatives over the last few years. Most recently they were members of the deal team focused on closing a complex global divestiture of a gastrointestinal pharmaceutical business. Bourne Partners market knowledge, experience and strategic advice were instrumental in bringing the deal to a successful close."

    Lucantonio Salvi, Partner, Sheppard Mullin Richter & Hampton LLP

  • "I had the opportunity to work closely with Banks and his team at Bourne Partners and thoroughly enjoyed the experience. Banks and his group worked tirelessly demonstrating integrity and insight throughout the assignment. It would be my pleasure to work with Bourne Partners again in the future."

    Henry McCarthy, Director, Strategic Planning & Operations, GlaxoSmithKline

  • "I have known Banks and the Bourne Partners team for many years both as an advisor and investor in the healthcare arena. They are a knowledgeable and energetic group that is well traveled in the space. In addition, Banks has been a supporter of UHS (Universal Hospital Services) and National Surgical Hospitals as a limited partner in Irving Place Capital."

    David Crane, Chief Executive Officer, National Surgical Hospitals

  • "We continue to be impressed by Bourne’s straight forward approach and fantastic connections to major industry players. Bourne Capital Partners illustrates exactly the type of companies and management teams that we seek to partner with."

    J.R. Kingsley Ward, Chairman, Convergent Healthcare

  • "We worked across the table from the team at Bourne Partners during our licensing of the European development and commercialization rights to our lead product, Sumatriptan DosePro. Their team was always professional and their bankers understood the intricacies of a cross border transaction. Bourne Partners’ expertise and diligent approach helped drive this transaction to a timely close."

    Jonathan Rigby, Chief Executive Officer, SteadyMed Therapeutics, Inc.

  • "Banks and his firm, Bourne Partners, continue to be our go to partner for strategic advisory services in the Rx Health Care space. Banks’ extensive network, creativity and passion adds great value to any potential transaction. The Bourne team is smart, responsive and available when you need them."

    Steve Ruhf, Chief Business Development Officer, Fleet Laboratories

  • "I have evaluated multiple strategic investment opportunities in conjunction with Bourne Partners.  Their financial acumen, industry contacts and insight have been of great value to Carolinas HealthCare System."

    Tye Nordberg, VP, Strategic Development and Investment, Carolinas HealthCare System

  • "Bourne Partners managed the initiative of selling our privately held company during 2013.  The knowledge and leadership of the entire Bourne Staff as they directed the efforts of the organization, assembling the presentation of our company’s offering made the entire process relatively simple.  We were able to continue to manage and grow our business while Bourne Partners focused on finding an acquirer that understood and appreciated what we had to offer as a company.  My partners and I credit Bourne Partners’ reputation, professionalism and industry contacts with the successful results of our transaction."

    Larry Chriscoe, President, NFI Consumer Products

  • "We have worked with Bourne Partners since 2004, most recently as an extension of our core business development team working to license and acquire assets from US domiciled companies in the CNS category.  Their hard work, in depth sector knowledge, seamless integration with our executive team and relationships within the specialty pharmaceutical market have made them a true asset to our organization."

    Harald Jainta, Director of Business Development, Desitin Arzneimittel GmbH

  • "I like working with Bourne Partners. They are very knowledgeable about the relevant trends in healthcare."

    Michael Wells, Director, Covis Pharma S.a.r.l.

  • "It is my pleasure to write this recommendation for Banks and Bourne Partners. We regularly work with industry leaders in our area of medicine. I can say unequivocally that Banks' vision, drive, and competence set him apart. When coupled with a good knowledge of the area, he is a formidable presence in the biomedical space. I would recommend him without reservation."

    David Armstrong, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance at University of Arizona

  • "Bourne Partners understands the healthcare sector extremely well and are genuine people of high integrity."

    John King, Founder and Non-executive Chairman, Warner Chilcott

  • "We enjoyed working with the Bourne Partners team to evaluate strategic alternatives and partnering strategies for select products in our portfolio."

    Claes Thulin, Chief Executive Officer, BioPhausia AB

  • "Banks is one of the most impressive business men that I have ever met. He is a great leader which makes it truly a pleasure to partner with his company. I have been following and working in projects with Bourne Partners for about 10 years now and it is a great organization. Its professionals are full of drive and knowledge. Commitment, candor and hard work are part of their DNA. For me it is not a surprise that they keep delivering great results through the years."

    Daniel Feliciano Ferreira, International Division Director, Germed Pharma Europe (EMS Group)

  • "Banks is great guy to work with and has been a valuable asset to us in our recent Covis investment both as a BOD member and as an advisor. He's well connected and has a strong knowledge of the healthcare landscape."

    Alex Faherty, Vice President, Cerberus Capital Management